Drug Trial Radar · NCT06381986
Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Jun 28, 2024
Primary completion
Apr 10, 2025
Study completion Apr 17, 2025
Sponsor
- Lead sponsor
- Sunhawk Vision Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure efficacy and safety with 0.25% SHJ002 sterile ophthalmic solution compared to vehicle in treating corneal erosion in Sjogren's patients. SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
Conditions
- Corneal Erosion
Interventions
SHJ002Drug
Topical ophthalmic
VehicleOther
Topical ophthalmic
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Total Corneal Fluorescein StainingTime frame: Baseline to Week 12
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Kaohsiung Medical Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
Chang Gung Memorial Hospital-Tu Cheng
New Taipei City, Taiwan
MacKay Memorial Hospital
Taipei, Taiwan
Cathay General Hospital
Taipei, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.